Combination Therapies Targeting Alk-Aberrant Neuroblastoma in Preclinical Models.
Elizabeth R TuckerIrene JiménezLindi ChenAngela BelliniChiara GorriniElizabeth A CaltonQiong GaoHarvey CheEvon PoonYann JaminBarbara Martins Da CostaKaren BarkerSumana ShresthaJohn Ciaran HutchinsonSimran DhariwalAngharad GoodmanElaine Del NeryPierre GestraudJaydutt BhalshankarYasmine IddirElnaz Saberi-AnsariAlexandra Saint-CharlesDidier FrappazMaria Eugénia Marques da CostaCecile Pierre-EugeneIsabelle Janoueix-LeroseyDidier DecaudinFariba NematiAngel Montero CarcabosoDidier SurdezOlivier O DelattreSally L GeorgeLouis CheslerDeborah A TweddleGudrun SchleiermacherPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
In our preclinical neuroblastoma models, high ALK expression was associated with lorlatinib response alone or in combination with either chemotherapy or idasanutlin. The synergy between MDM2 and ALK inhibition warrants further evaluation of this combination as a potential clinical approach for children with neuroblastoma.